# Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa

> **NCT03730584** · NA · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 10 (actual)

## Conditions studied

- Epidermolysis Bullosa

## Interventions

- **DRUG:** Ropivacaine
- **BIOLOGICAL:** Blood test

## Key facts

- **NCT ID:** NCT03730584
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2019-11-28
- **Final completion:** 2019-11-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730584, "Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa". Retrieved via MORVS 2026-11-01 from https://api.morvs.ai/clinical/NCT03730584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*